EGFR and lung cancer: Our data implies possible low PD-L1 expression in TKI-refractory lesions without T790M mutation, and that can be one of the molecular mechanisms that attenuates the efficacy of PD-1/PD-L1 targeting agents in lung cancer patients with EGFR mutations.